EDAP Announces Presentation at the Jefferies Virtual London Healthcare Conference
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, announced its participation in the Jefferies Virtual London Healthcare Conference from November 17-19, 2020. The presentation is scheduled for November 17 at 10:00 am BT. A webcast of the event will be available for replay for 90 days. EDAP focuses on minimally invasive medical devices, including its Focal One® for prostate ablation and ExactVu™ Micro-Ultrasound. Potential risks include market acceptance of its HIFU devices and impacts from COVID-19 on demand.
- Participation in a recognized healthcare conference enhances visibility for EDAP.
- The Focal One® and ExactVu™ products position EDAP as a comprehensive solution provider for prostate cancer treatment.
- Market acceptance of HIFU devices remains uncertain.
- COVID-19 may negatively impact demand for EDAP's devices and services.
LYON, France, November 10, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the Jefferies Virtual London Healthcare Conference, which is being held November 17-19, 2020.
Presentation Details
Date: Tuesday, November 17
Time: 10:00am BT
Webcast: https://wsw.com/webcast/jeff141/edap/1815450
The webcast will be archived and available for replay for a period of 90 days.
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment such as the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the sustained activity of our lithotripsy business, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com
FAQ
When will EDAP present at the Jefferies Virtual London Healthcare Conference?
How can I access the EDAP presentation from the Jefferies conference?
What are the main products offered by EDAP?
What risks are mentioned in EDAP's press release related to COVID-19?
